Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857957 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN
A Phase 1 study, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04857957: Completed Phase 1 study, sponsored by Centrexion Therapeutics.
NCT04857957 is a Phase 1 study that has completed, run by Centrexion Therapeutics. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04857957, a Phase 1 study, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.
Primary Outcome
Number of participants with TEAEs, which includes laboratory test variables
Interventions
- DRUG Oral dose CNTX-6016 or oral dose Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 1 |
What the finished NCT04857957 record still lists
NCT04857957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 1 intervention - of which Oral dose CNTX-6016 or oral dose Placebo is the first listed.
NCT04857957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04857957 about?
NCT04857957 is a clinical study titled "Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN". A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.
What is the current status of trial NCT04857957?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-04-14. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT04857957?
The interventions under investigation include: Oral dose CNTX-6016 or oral dose Placebo (DRUG).
Who is sponsoring clinical trial NCT04857957?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04857957's enrollment target sits among peer trials
46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI